Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lyell Immunopharma, Inc. - Common Stock (NQ:LYEL)

12.31 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lyell Immunopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Participation in September Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
 
Via Benzinga
Lyell Immunopharma Inc (NASDAQ:LYEL) Reports Q2 2025 Earnings Beat with Clinical Progress on LYL314
Lyell Immunopharma reports Q2 2025 with a narrower loss than expected, driven by cost controls. Clinical progress for CAR T-cell therapy LYL314 remains strong, with pivotal trials advancing. Cash... 
Via Chartmill
Topics Earnings
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
From Lyell Immunopharma, Inc
Via GlobeNewswire
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
From Lyell Immunopharma, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Here are the top movers in Thursday's session.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
What's going on in today's session
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
What's going on in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. 
Via Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.